We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
Technopath Clinical Diagnostics - An LGC Company

Download Mobile App


ATTENTION: Due to the COVID-19 PANDEMIC, many events are being rescheduled for a later date, converted into virtual venues, or altogether cancelled. Please check with the event organizer or website prior to planning for any forthcoming event.

Affordable Blood-Based Test Provides Early Detection of Colorectal Cancer

By LabMedica International staff writers
Posted on 16 Mar 2023
Print article
Image: BeScreened-CRC is a screening test that aids in the detection of colorectal cancer (Photo courtesy of Beacon Biomedical)
Image: BeScreened-CRC is a screening test that aids in the detection of colorectal cancer (Photo courtesy of Beacon Biomedical)

Colorectal cancer (CRC) is the second most lethal and expensive cancer in the US, with over 150,000 new diagnoses and 50,000 deaths annually. Shockingly, of the 131 million Americans eligible for CRC screening each year, a massive 45 million opt out – accounting for 65% of CRC deaths and 75% of CRC treatment expenses (a hefty USD 18 billion each year) as well as lost productivity costs of USD 20 billion. Recent research has shown that 84% of the population prefers blood testing to fecal testing. Now, a newly-launched CRC blood test improves screening compliance and consequently, the probability of survival while sharply bringing down CRC treatment costs and eliminating the need for fecal collection.

Beacon Biomedical (Phoenix, AZ, USA) has announced the commercial release of the BeScreened Colorectal Cancer (CRC) test, a laboratory developed test (LDT) that meets the needs of average-risk men and women over 45 who prefer blood-based screening over colonoscopy or fecal-based tests. The BeScreened-CRC test is designed to drive improved compliance and early detection - which can result in survival rates of 90%, as against merely 14% if detected later. The test is the preferred blood-based modality, one of the most accurate tests in the industry with an accuracy rate of 94.6%, and is much more affordable than other available screening options.

"Too many lives are lost every year to colorectal cancer. The real tragedy is the majority of these deaths are preventable as they can be directly attributed to non-compliance with existing screening methods," said Don Weber, Founder & CEO of Beacon Biomedical. "As a simple, easy to adopt, and highly accurate blood-based test for CRC screening, BeScreened was developed to address this very problem."

Related Links:
Beacon Biomedical 

Gold Supplier
Multichannel Pipettes
Finnpipette Novus
UTI Culture Test
Multi-Drug Rapid Test
Multi-Drug Rapid Test
RF Latex Agglutination Test
rheumajet RF

Print article


Clinical Chem.

view channel
Image: Brief schematic diagram of the detection principle and method (Photo courtesy of CAS)

Rapid, Non-Invasive Method Diagnoses Type 2 Diabetes by Sniffing Urinary Acetone

Over 90% of diabetes cases are attributed to Type 2 diabetes (T2D), a prevalent metabolic condition that is expected to impact 380 million individuals globally by 2025. Despite being highly accurate, the... Read more


view channel
Image: A genetic test could guide the use of cancer chemotherapy (Photo courtesy of Pexels)

Genetic Test Predicts Whether Bowel Cancer Patients Can Benefit From Chemotherapy

Late-stage bowel cancer patients usually undergo a series of chemotherapies and targeted medicines for cancer treatment. However, the responses to the last-line chemotherapy treatment trifluridine/tipiracil... Read more


view channel
Image: Sampling a single stool using multiple PCR panels can identify more pathogens rapidly (Photo courtesy of Pexels)

PCR Panels for Acute GI Infections Can Lower Costs, Hospitalization and Antibiotic Use

Acute gastroenteritis impacts adults across all age groups and incurs enormous healthcare expenses. Now, a new study comprising 40,000 hospital visits across various geographic locations has revealed that... Read more


view channel
Image: Artificial intelligence predicts genetics of cancerous brain tumors in under 90 seconds (Photo courtesy of Michigan Medicine)

AI-Based Diagnostic Screening System Predicts Genetics of Cancerous Brain Tumors in 90 Seconds

The diagnosis and treatment of gliomas increasingly rely on molecular classification, as surgical benefits and risks vary depending on a patient's genetic makeup. Complete removal of the tumor can extend... Read more


view channel
Image: Live view of non-fluorescent specimens using the glowscope frame (Photo courtesy of Winona State University)

Device Converts Smartphone into Fluorescence Microscope for Just USD 50

Fluorescence microscopes are utilized to examine specimens labeled with fluorescent stains or expressing fluorescent proteins, like those tagged with green fluorescent protein. However, since these microscopes... Read more


view channel
Image: Roche and Lilly will collaborate on the development of Roche Diagnostics’ Elecsys Amyloid Plasma Panel (Photo courtesy of Roche)

Roche and Eli Lilly Collaborate on Innovative Blood Test for Early Diagnosis of Alzheimer's

Presently, obstacles to timely and precise diagnosis of Alzheimer's disease exist globally, resulting in as many as 75% of individuals exhibiting symptoms but lacking a formal diagnosis.... Read more
Copyright © 2000-2023 Globetech Media. All rights reserved.